Incidence and risk factors of retreatment after three-monthly aflibercept therapy for exudative age-related macular degeneration.

ABSTRACT: Though anti-vascular endothelial growth factor therapy has become the standard treatment for exudative age-related macular degeneration (AMD), retreatment after the initial loading injection is inevitable in most eyes with residual or recurrent exudative changes. In the present study, we studied 140 treatment naïve eyes with typical neovascular AMD (n = 71) or polypoidal choroidal vasculopathy (PCV) (n = 69) and investigated the incidence and risk factors of retreatment after 3-monthly intravitreal aflibercept injection for exudative AMD during the 12-month period. At 12 months, best-corrected visual acuity (BCVA) improved significantly from 0.45 ± 0.39 to 0.26 ± 0.33 (P = 4.1 × 10^-11). Multiple regression analysis revealed that better baseline BCVA (P = 3.6 × 10^-14)

SUBMITTER: Kikushima W 

PROVIDER: S-EPMC5339812 | biostudies-literature | 2017 Mar

REPOSITORIES: biostudies-literature